These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Immunogenicity and safety of the RTS,S/AS01 malaria vaccine co-administered with measles, rubella and yellow fever vaccines in Ghanaian children: A phase IIIb, multi-center, non-inferiority, randomized, open, controlled trial. Asante KP; Ansong D; Kaali S; Adjei S; Lievens M; Nana Badu L; Agyapong Darko P; Boakye Yiadom Buabeng P; Boahen O; Maria Rettig T; Agutu C; Benard Ekow Harrison S; Ntiamoah Y; Adomako Anim J; Adeniji E; Agordo Dornudo A; Gvozdenovic E; Dosoo D; Sambian D; Owusu-Boateng H; Ato Wilson E; Prempeh F; Vandoolaeghe P; Schuerman L; Owusu-Agyei S; Agbenyega T; Ofori-Anyinam O Vaccine; 2020 Apr; 38(18):3411-3421. PubMed ID: 32192811 [TBL] [Abstract][Full Text] [Related]
5. Policy uptake and implementation of the RTS,S/AS01 malaria vaccine in sub-Saharan African countries: status 2 years following the WHO recommendation. Osoro CB; Ochodo E; Kwambai TK; Otieno JA; Were L; Sagam CK; Owino EJ; Kariuki S; Ter Kuile FO; Hill J BMJ Glob Health; 2024 Apr; 9(4):. PubMed ID: 38688566 [TBL] [Abstract][Full Text] [Related]
6. Safety and immunogenicity of RTS,S/AS01 malaria vaccine in infants and children with WHO stage 1 or 2 HIV disease: a randomised, double-blind, controlled trial. Otieno L; Oneko M; Otieno W; Abuodha J; Owino E; Odero C; Mendoza YG; Andagalu B; Awino N; Ivinson K; Heerwegh D; Otsyula N; Oziemkowska M; Usuf EA; Otieno A; Otieno K; Leboulleux D; Leach A; Oyieko J; Slutsker L; Lievens M; Cowden J; Lapierre D; Kariuki S; Ogutu B; Vekemans J; Hamel MJ Lancet Infect Dis; 2016 Oct; 16(10):1134-1144. PubMed ID: 27394191 [TBL] [Abstract][Full Text] [Related]
7. Estimated impact of RTS,S/AS01 malaria vaccine allocation strategies in sub-Saharan Africa: A modelling study. Hogan AB; Winskill P; Ghani AC PLoS Med; 2020 Nov; 17(11):e1003377. PubMed ID: 33253211 [TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of the RTS,S/AS01E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial. Asante KP; Abdulla S; Agnandji S; Lyimo J; Vekemans J; Soulanoudjingar S; Owusu R; Shomari M; Leach A; Jongert E; Salim N; Fernandes JF; Dosoo D; Chikawe M; Issifou S; Osei-Kwakye K; Lievens M; Paricek M; Möller T; Apanga S; Mwangoka G; Dubois MC; Madi T; Kwara E; Minja R; Hounkpatin AB; Boahen O; Kayan K; Adjei G; Chandramohan D; Carter T; Vansadia P; Sillman M; Savarese B; Loucq C; Lapierre D; Greenwood B; Cohen J; Kremsner P; Owusu-Agyei S; Tanner M; Lell B Lancet Infect Dis; 2011 Oct; 11(10):741-9. PubMed ID: 21782519 [TBL] [Abstract][Full Text] [Related]
9. Safety of the malaria vaccine candidate, RTS,S/AS01E in 5 to 17 month old Kenyan and Tanzanian Children. Lusingu J; Olotu A; Leach A; Lievens M; Vekemans J; Olivier A; Benns S; Olomi R; Msham S; Lang T; Gould J; Hallez K; Guerra Y; Njuguna P; Awuondo KO; Malabeja A; Abdul O; Gesase S; Dekker D; Malle L; Ismael S; Mturi N; Drakeley CJ; Savarese B; Villafana T; Ballou WR; Cohen J; Riley EM; Lemnge MM; Marsh K; Bejon P; von Seidlein L PLoS One; 2010 Nov; 5(11):e14090. PubMed ID: 21124768 [TBL] [Abstract][Full Text] [Related]
10. Integration of the RTS,S/AS01 malaria vaccine into the Essential Programme on Immunisation in western Kenya: a qualitative longitudinal study from the health system perspective. Hill J; Bange T; Hoyt J; Kariuki S; Jalloh MF; Webster J; Okello G Lancet Glob Health; 2024 Apr; 12(4):e672-e684. PubMed ID: 38430916 [TBL] [Abstract][Full Text] [Related]
11. Design of a phase III multicenter trial to evaluate the efficacy of the RTS,S/AS01 malaria vaccine in children across diverse transmission settings in Africa. Leach A; Vekemans J; Lievens M; Ofori-Anyinam O; Cahill C; Owusu-Agyei S; Abdulla S; Macete E; Njuguna P; Savarese B; Loucq C; Ballou WR; Malar J; 2011 Aug; 10():224. PubMed ID: 21816029 [TBL] [Abstract][Full Text] [Related]
12. Environmental modifiers of RTS,S/AS01 malaria vaccine efficacy in Lilongwe, Malawi. Bell GJ; Loop MS; Mvalo T; Juliano JJ; Mofolo I; Kamthunzi P; Tegha G; Lievens M; Bailey J; Emch M; Hoffman I BMC Public Health; 2020 Jun; 20(1):910. PubMed ID: 32532234 [TBL] [Abstract][Full Text] [Related]
13. Public health impact and cost-effectiveness of the RTS,S/AS01 malaria vaccine: a systematic comparison of predictions from four mathematical models. Penny MA; Verity R; Bever CA; Sauboin C; Galactionova K; Flasche S; White MT; Wenger EA; Van de Velde N; Pemberton-Ross P; Griffin JT; Smith TA; Eckhoff PA; Muhib F; Jit M; Ghani AC Lancet; 2016 Jan; 387(10016):367-375. PubMed ID: 26549466 [TBL] [Abstract][Full Text] [Related]
14. [The RTS,S/AS01 malaria vaccine in children aged 5-17 months at first vaccination]. Vandoolaeghe P; Schuerman L Pan Afr Med J; 2018; 30():142. PubMed ID: 30374388 [TBL] [Abstract][Full Text] [Related]
16. Cost of introducing and delivering RTS,S/AS01 malaria vaccine within the malaria vaccine implementation program. Baral R; Levin A; Odero C; Pecenka C; Tanko Bawa J; Antwi-Agyei KO; Amponsa-Achaino K; Chisema MN; Eddah Jalango R; Mkisi R; Gordon S; Morgan W; Muhib F Vaccine; 2023 Feb; 41(8):1496-1502. PubMed ID: 36710234 [TBL] [Abstract][Full Text] [Related]
17. Implementation strategies for the introduction of the RTS,S/AS01 (RTS,S) malaria vaccine in countries with areas of highly seasonal transmission: workshop meeting report. Merle CS; Malar J; 2023 Aug; 22(1):242. PubMed ID: 37612716 [TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. RTS,S Clinical Trials Partnership Lancet; 2015 Jul; 386(9988):31-45. PubMed ID: 25913272 [TBL] [Abstract][Full Text] [Related]
19. Long-term incidence of severe malaria following RTS,S/AS01 vaccination in children and infants in Africa: an open-label 3-year extension study of a phase 3 randomised controlled trial. Tinto H; Otieno W; Gesase S; Sorgho H; Otieno L; Liheluka E; Valéa I; Sing'oei V; Malabeja A; Valia D; Wangwe A; Gvozdenovic E; Guerra Mendoza Y; Jongert E; Lievens M; Roman F; Schuerman L; Lusingu J Lancet Infect Dis; 2019 Aug; 19(8):821-832. PubMed ID: 31300331 [TBL] [Abstract][Full Text] [Related]